drugset / Trial / NCT05957536
A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This first-in-human (FIH) study, multi-center, open-label, dose escalation and dose expansion Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary anti-tumor activity of D3L-001 in subjects with HER2-positive advanced solid tumors.
Timeline
- Start
- 2023-09-19
- Primary completion
- 2028-12-19
- Completion
- 2028-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | D3L-001 | Unknown | — | Intravenous |
Indications
No indication recorded.